Thr99

Site Information
AEyVVEstGVFttME SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 23109029

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:	colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , esophageal cancer ( 2 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 1 ) , esophagus ( 2 ) , HCT116 (intestinal) ( 1 ) , SW48 (intestinal) ( 1 )

Downstream Regulation
Effects of modification on GAPDH:	enzymatic activity, induced ( 1 )

References
1	Phadke M, et al. (2015) Disruption of NAD(+) binding site in glyceraldehyde 3-phosphate dehydrogenase affects its intranuclear interactions. World J Biol Chem 6, 366-78 26629320 Curated Info
2	Gu T (2009) CST Curation Set: 7091; Year: 2009; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info

References

Phadke M, et al. (2015) Disruption of NAD(+) binding site in glyceraldehyde 3-phosphate dehydrogenase affects its intranuclear interactions. World J Biol Chem 6, 366-78
26629320 Curated Info

Gu T (2009) CST Curation Set: 7091; Year: 2009; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info